Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Comprehensive pharmacological screening of curcumin (CUR) has given the evidence that it is an excellent naturally occurring therapeutic moiety for cancer. It is very well tolerated with insignificant toxicity even after high doses of oral administration. Irrespective of its better quality as an anticancer agent, therapeutic application of CUR is hampered by its extremely low-aqueous solubility and poor bioavailability, rapid clearance and low-cellular uptake. A simple means of breaking up the restrictive factor of CUR is to perk-up its aqueous solubility, improve its bioavailability, protect it from degradation, and metabolism and potentiate its targeting capacity towards the cancer cell. The development in the field of nanomedicine has made excellent progresses toward enhancing the bioavailability of lipophilic drugs like CUR. Nanoparticles (NPs) are capable to deliver the CUR at specific area and thereby prevent it from physiological degradation and systemic clearance. In recent year, an assortment of nanomedicine-based novel drug delivery system has been designed to potentiate the bioavailability of CUR towards anticancer therapy. In this review, we discuss the recent development in the field of nanoCUR (NanoCur), including polymeric micelles, liposome, polymeric NPs, nanoemulsion, nanosuspension, solid lipid NPs (SLNPs), polymer conjugates, nanogel, etc. in anticancer application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Sood, S., Jain, K., & Gowthamarajan, K. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.09.030 · Cited by 289
Coradini, K., Lima, F. O., Oliveira, C. M., Chaves, P. S., Athayde, M. L., Carvalho, L. M., & Beck, R. C. R. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.04.009 · Cited by 200
Duan, J., Mansour, H. M., Zhang, Y., Deng, X., Chen, Y., Wang, J., Pan, Y., & Zhao, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.01.020 · Cited by 194
Kumar, A., Ahuja, A., Ali, J., & Baboota, S. (2016) · Drug Delivery · doi:10.3109/10717544.2014.909906 · Cited by 76
Cited by
Hussain, Z., Thu, H. E., Amjad, M. W., Hussain, F., Ahmed, T. A., & Khan, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.03.226 · Cited by 281
Polymeric micelles of biodegradable diblock copolymers: enhanced encapsulation of hydrophobic drugs
Hussein, Y. H. A., & Youssry, M. (2018) · Materials · doi:10.3390/ma11050688 · Cited by 196
Nanoparticles guided drug delivery and imaging in gastric cancer
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.006 · Cited by 62
McClure, R., Ong, H., Janve, V., Barton, S., Zhu, M., Li, B., Dawes, M., Jerome, W. G., Anderson, A., Massion, P., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160289 · Cited by 54
Metadata
- Authors
- Ahmad, M. Z., Alkahtani, S. A., Akhter, S., Ahmad, F. J., Ahmad, J., Akhtar, M. S., Mohsin, N., & Abdel-Wahab, B. A.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2015-06-11
- Volume
- 24
- Issue
- 4
- Pages
- 273-293
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W1766544245
- Cited by
- 87
- References
- 5
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. https://app.cochat.ai/papers/10.3109/1061186x.2015.1055570
- The paper
- Ahmad, M. Z., Alkahtani, S. A., Akhter, S., Ahmad, F. J., Ahmad, J., Akhtar, M. S., Mohsin, N., & Abdel-Wahab, B. A. (2016). Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. Journal of Drug Targeting. https://doi.org/10.3109/1061186x.2015.1055570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.